Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Lara,Humberto H.; Ixtepan-Turrent,Liliana; Garza-Treviño,Elsa N.; Tamez-Guerra,Reyes; Rodriguez-Padilla,Cristina

doi:10.3892/etm_00000066

Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Authors:
- Humberto H. Lara
- Liliana Ixtepan-Turrent
- Elsa N. Garza-Treviño
- Reyes Tamez-Guerra
- Cristina Rodriguez-Padilla
View Affiliations

Affiliations: Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Universidad Autonoma de Nuevo Leon, Nuevo Leon, Mexico. dr.lara.v@gmail.com
Published online on: May 1, 2010 https://doi.org/10.3892/etm_00000066
Pages: 425-431

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dialyzable leukocyte extract (DLE) is one of the immunological agents used as an adjuvant in cancer therapy; it has been associated with improved quality of life during cancer chemotherapy. Based on these previous findings and on the observed clinical benefits attributed to DLE in other types of cancer, we investigated its clinical and immunological effects as a therapy adjuvant on breast cancer patients who received only chemotherapy, as compared to patients administered bovine DLE (bDLE) as an adjuvant. This study included 43 breast cancer patients who were about to begin chemotherapy. This group was divided as follows: 25 received chemotherapy and bDLE as an adjuvant therapy, and 18 received only chemotherapy without the adjuvant. All patient clinical and immunological responses were monitored. Among patients in the group that received bDLE as adjuvant, 60% showed a complete response, 32% showed a partial response and 8% did not respond. By contrast, in the group without the adjuvant, 39% showed a complete response, 50% displayed a partial response and 11% were non-responders. In addition, bDLE treatment in combination with chemotherapy resulted in the enhancement of the Karnofsky performance scale during chemotherapy. Even though patients underwent several cycles of chemotherapy without bDLE, the lymphocyte population dropped to below the reference value. On the other hand, in patients with bDLE as adjuvant, the CD4+ and CD8+ lymphocytes and the B lymphocytes were maintained within the median range of the reference value. The number of natural killer cells also increased after chemotherapy treatment with bDLE as an adjuvant. In conclusion, bDLE treatment contributes to significant immunological recovery in patients that have undergone heavy chemotherapy, increasing the clinical response and quality of life during chemotherapy.

View Figures

View References

1.	Bray F, McCarron P and Parkin DM: The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 6:229–239. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Stewart BW and Coates AS: Cancer prevention: a global perspective. J Clin Oncol. 23:392–403. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Smith MD and McGhan WF: Financial facts about treating breast cancer. Bus Health. 14:67–68. 70:1996.PubMed/NCBI
4.	Spitler LE: Clinical uses of transfer factor. Calif Med. 118:471973.PubMed/NCBI
5.	Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL and Gress RE: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 84:2221–2228. 1994.PubMed/NCBI
6.	Van der Most RG, Currie AJ, Robinson BW and Lake RA: Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 15:13–20. 2008.PubMed/NCBI
7.	Piper BF, Borneman T, Sun VC, Koczywas M, Uman G, Ferrell B and James RL: Cancer-related fatigue: role of oncology nurses in translating National Comprehensive Cancer Network Assessment Guidelines into practice. Clin J Oncol Nurs. 12:37–47. 2008. View Article : Google Scholar
8.	Berger AM: Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum. 25:51–62. 1998.PubMed/NCBI
9.	Goodman MN: Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol. 260:E727–E730. 1991.PubMed/NCBI
10.	Karnofsky DA, Abelmann WH and Craver LF: The use of the nitrogen mustards in palliative treatment of carcinoma. Cancer. 1:634–656. 1948. View Article : Google Scholar
11.	Priestman TJ and Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet. 1:899–900. 1976. View Article : Google Scholar : PubMed/NCBI
12.	Kasper CE: Sarcolemmal disruption in reloaded atrophic skeletal muscle. J Appl Physiol. 79:607–614. 1995.PubMed/NCBI
13.	Kasper CE: Recovery of plantaris muscle from impaired physical mobility. Biol Res Nurs. 1:4–11. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Kasper CE and Sarna LP: Influence of adjuvant chemotherapy on skeletal muscle and fatigue in women with breast cancer. Biol Res Nurs. 2:133–139. 2000. View Article : Google Scholar : PubMed/NCBI
15.	St Pierre BA, Kasper CE and Lindsey AM: Fatigue mechanisms in patients with cancer: effects of tumor necrosis factor and exercise on skeletal muscle. Oncol Nurs Forum. 19:419–425. 1992.PubMed/NCBI
16.	Lawrence HS and Borkowsky W: Transfer factor – current status and future prospects. Biotherapy. 9:1–5. 1996.
17.	Kirkpatrick CH: Transfer of cellular immunity with transfer factor. J Allergy Clin Immunol. 63:71–73. 1979. View Article : Google Scholar : PubMed/NCBI
18.	Vacek A, Hofer M, Schneiderova H and Svoboda J: Ultrafiltered pig leukocyte extract (UPLE, IMUNOR) potentiates hematopoiesis-stimulating effects of G-CSF in vitro and improves the outcome of treatment of hematopoietic radiation damage in mice with G-CSF. Immunopharmacol Immunotoxicol. 27:647–659. 2005. View Article : Google Scholar
19.	Pizzo PA, Henderson ES and Leventhal BG: Acute myelogenous leukemia in children: a preliminary report of combination chemotherapy. J Pediatr. 88:125–130. 1976. View Article : Google Scholar : PubMed/NCBI
20.	Franco-Molina MA, Mendoza-Gamboa E, Castillo-Leon L, Tamez-Guerra RS and Rodriguez-Padilla C: Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock. Int Immunopharmacol. 4:1577–1586. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Atzpodien J, Kuchler T, Wandert T and Reitz M: Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer. 89:50–54. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Ojeda MO, van't Veer C, Fernandez Ortega CB, Arana Rosainz MJ and Buurman WA: Dialyzable leukocyte extract differentially regulates the production of TNFalpha, IL-6 and IL-8 in bacterial component-activated leukocytes and endothelial cells. Inflamm Res. 54:74–81. 2005. View Article : Google Scholar
23.	Kirkpatrick CH, Rozzo SJ, Mascali JJ and Merryman CF: Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. J Immunol. 134:1723–1727. 1985.PubMed/NCBI
24.	Kirkpatrick CH: Therapeutic potential of transfer factor. N Engl J Med. 303:390–391. 1980. View Article : Google Scholar : PubMed/NCBI
25.	Kirkpatrick CH: Transfer of delayed cutaneous hypersensitivity with transfer factor. Cell Immunol. 41:62–71. 1978. View Article : Google Scholar : PubMed/NCBI
26.	Franco-Molina MA, Mendoza-Gamboa E, Miranda-Hernandez D, Zapata-Benavides P, Castillo-Leon L, Isaza-Brando C, Tamez-Guerra RS and Rodriguez-Padilla C: In vitro effects of bovine dialyzable leukocyte extract (BDLE) in cancer cells. Cytotherapy. 8:408–414. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Mendoza-Gamboa E, Franco-Molina MA, Zapata-Benavides P, Castillo-Tello P, Vera-Garcia ME, Tamez-Guerra RS and Rodriguez-Padilla C: Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells. Cytotherapy. 10:212–219. 2008. View Article : Google Scholar
28.	Oettgen HF, Old LJ, Farrow JH, Valentine FT, Lawrence HS and Thomas L: Effects of dialyzable transfer factor in patients with breast cancer. Proc Natl Acad Sci USA. 71:2319–2323. 1974. View Article : Google Scholar : PubMed/NCBI
29.	Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R and Arrieta O: Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res. 24:575–583. 2005.PubMed/NCBI
30.	Meier CR and LoBuglio AF: Transfer factor: a potential agent for immunotherapy of cancer. World J Surg. 1:617–623. 1977. View Article : Google Scholar : PubMed/NCBI
31.	Goldenberg GJ and Brandes LJ: In vivo and in vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor. Cancer Res. 36:720–723. 1976.PubMed/NCBI
32.	Moss RW: Cancer and complementary and alternative medicine in Italy: personal observations and historical considerations. Integr Cancer Ther. 3:173–188. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Pizza G, De VC, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E and LoConte G: A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy. 9:123–132. 1996. View Article : Google Scholar : PubMed/NCBI
34.	Rodriguez-Flores A, Castillo-Juarez P, Vazquez D, Gonzalez-Guzman R, Rico-Martinez G and Estrada-Parra S: Immunological evaluation of patients with osteosarcoma received adjuvant treatment with specific transfer factor. J Immunol. 182:632009.
35.	Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE and Mavroukakis SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 23:2346–2357. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-Garcia ME, Castillo-Tello P, Garcia dlF, Mendoza RD, Garza RG, Tamez-Guerra RS and Rodriguez-Padilla C: IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy. 10:490–496. 2008. View Article : Google Scholar : PubMed/NCBI
37.	Fujisawa T: Transfer factor immunotherapy as an adjunct to surgery in lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 23:68–73. 1985.PubMed/NCBI
38.	Krown SE, Pinsky CM, Hirshaut Y, Hansen JA and Oettgen HF: Effects of transfer factor in patients with advanced cancer. Isr J Med Sci. 14:1026–1038. 1978.PubMed/NCBI
39.	Vacek A, Hofer M, Hola J, Weiterova L, Streitova D and Svoboda J: The role of G-CSF and IL-6 in the granulopoiesis-stimulating activity of murine blood serum induced by perorally administered ultrafiltered pig leukocyte extract, IMUNOR. Int Immunopharmacol. 7:656–661. 2007. View Article : Google Scholar